Skip to main content
Back to News Hub
🟢TechCrunch AI
November 17, 2026
Funding & Investment

Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

Overview

Isomorphic Labs has raised $5 billion in a Series C funding round to advance its computational healthcare work. The artificial intelligence drug-discovery platform was originally spun out of Google's DeepMind in 2021. The fresh capital will allow the company to progress its drug candidates into clinical trials.

Key Takeaways

  • Isomorphic Labs has completed a $5 billion Series C funding round, as reported on November 17, 2026.

    Spun out of Google's DeepMind in 2021, the company focuses on using artificial intelligence to accelerate the discovery of new medicines.

  • The main objective for this new investment is to take potential drug candidates into clinical trials.

    This move marks a major milestone in transitioning AI-designed treatments from preliminary computational models into real-world human testing, illustrating how AI research directly impacts medical development.

  • Isomorphic Labs raised $5 billion in a Series C funding round to support its AI drug-discovery platform.

    The company was originally created as a spinout from Google's DeepMind in 2021.

  • The newly raised capital will help Isomorphic Labs move its prospective drug candidates into clinical trials.
  • This substantial financial backing underscores growing confidence in computational approaches to biotechnology.

Stats & Key Facts

  • #Isomorphic Labs has raised $5 billion in a Series C funding round to advance its computational healthcare work.
  • #Isomorphic Labs has completed a $5 billion Series C funding round, as reported on November 17, 2026.
  • #Isomorphic Labs raised $5 billion in a Series C funding round to support its AI drug-discovery platform.

Isomorphic Labs has completed a $5 billion Series C funding round, as reported on November 17, 2026. Spun out of Google's DeepMind in 2021, the company focuses on using artificial intelligence to accelerate the discovery of new medicines. This substantial financial backing underscores growing confidence in computational approaches to biotechnology.

The main objective for this new investment is to take potential drug candidates into clinical trials. This move marks a major milestone in transitioning AI-designed treatments from preliminary computational models into real-world human testing, illustrating how AI research directly impacts medical development. Isomorphic Labs raised $5 billion in a Series C funding round to support its AI drug-discovery platform.

For more details please read the original article at TechCrunch AI.

Continue Learning

Comments

Comments appear only after moderation. Your email identifies your submission to the moderator and is never displayed here.

No approved comments yet.

Originally published by TechCrunch AI
Read the original